AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12468775
Drug: ZK200775 (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZK200775 (dose group 1: 262.5 mg in 48 hours)
Trial: 12468775
Drug: ZK200775 (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZK200775 (dose group 3: 105 mg over 6 hours)
Trial: 7609861
Drug: Amitriptyline (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (up to 100 mg/day)
Trial: 2559129
Drug: Cepharanthin (Ceph.)
RxNorm normalized name: Cephalanthus occidentalis bark extract
DrugBank: Cepharanthine (DB16824)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Cepharanthin (Ceph.) at a dose of 1 mg/kg
Trial: 619829
Drug: Nurse intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse intervention to improve medication compliance
Trial: 19502023
Drug: Transdermal scopolamine
RxNorm normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal scopolamine (TDS) patch
Trial: 16838228
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of tolevamer per day
Trial: 16838228
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g of tolevamer per day
Trial: 16838228
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of vancomycin per day
Trial: 9205815
Drug: Labetalol (0.99
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (0.99 mg per kg of IBW)
Trial: 9205815
Drug: Nebivolol (0.073
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (0.073 mg per kg of IBW)
Trial: 3763079
Drug: 2000 mL
RxNorm normalized name: TPN Bag 2000 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mL Plasma‐Lyte A
Trial: 3763079
Drug: 1000 mL
RxNorm normalized name: TPN Bag 1000 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mL 5% albumin (colloid infusion)
Trial: 3763079
Drug: 1000 mL
RxNorm normalized name: TPN Bag 1000 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mL Plasma‐Lyte A
Trial: 30179153
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (combined aspirin, clopidogrel and dipyridamole)
Trial: 30179153
Drug: Guideline therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline therapy (combined aspirin and dipyridamole, or clopidogrel alone)
Trial: 12860493
Drug: Adalimumab 0.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 0.25, 0.5, 1, 3, or 5 mg/kg i.v.
Trial: 6839972
Drug: Atrioventricular sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrioventricular sequential pacemaker (group B)
Trial: 24960402
Drug: Pertuzumab 840
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pertuzumab 840 mg for cycle 1 and 420 mg q3w for cycles 2‐6 (Arm A)
Trial: 9475319
Drug: Cord insulin-like
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cord insulin-like growth factor-I or glucagon concentrations
Trial: 2963522
Drug: Celiprolol (200,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (200, 400 or 600 mg once daily)
Trial: 2963522
Drug: Chlorthalidone (12.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (12.5, 25 or 37.5 mg once daily)
Trial: 15196519
Drug: Light touch
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light touch (L)
Trial: 11743267
Drug: Dopamine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine (3 microg./kg. per minute infusion)
Trial: 9718103
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment and 12-step groups
Trial: 9718103
Drug: Outpatient mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient mental health treatment and 12-step group attendance
Trial: 7655203
Drug: Topical therapy
RxNorm normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical therapy with prednisolone 1% eye drops (Inflanefran forte) 5 times per day
Trial: 7655203
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection of 4 mg dexamethasone (Fortecortin) immediately at the end of surgery; topical therapy as in group A
Trial: 5801346
Drug: Intraperitoneal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal fluid infusion with normal saline and 28 mEq of potassium chloride per litre
Trial: 5801346
Drug: Intraperitoneal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal fluid infusion with half-strength Darrow's solution
Trial: 16453248
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of Jarsin (extract of St John's wort)
Trial: 16453248
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of Jarsin (extract of St John's wort)
Trial: 15278047
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg per day for 7 days
Trial: 15278047
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg per day for 28 days
Trial: 8449588
Drug: Teicoplanin therapy
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin therapy (800 mg initially, then 400 mg at weekly intervals)
Trial: 3300316
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg three times a day
Trial: 3300316
Drug: Trimethoprim/sulfamethoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim/sulfamethoxazole (160 mg/800 mg) twice daily
Trial: 3300316
Drug: Norfloxacin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (both doses)
Trial: 28601972
Drug: TAK-228 8-mg
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-228 8-mg QDx3d QW plus paclitaxel 80 mg/m2
Trial: 28601972
Drug: TAK-228 10-mg
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-228 10-mg QDx3d QW plus paclitaxel 80 mg/m2
Trial: 24192332
Drug: Zidovudine during
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine during pregnancy plus single-dose nevirapine (sd-NVP) at labour
Trial: 18176972
Drug: Rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4 mg/d plus 5-ASA 2 g/d daily for 4 weeks
Trial: 18176972
Drug: 5-ASA 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ASA 2 g/d alone for 4 weeks
Trial: 12683261
Drug: Dietary supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplementation with a combination of AA (Arachidonic Acid) and DHA (Docosahexaenoic Acid) and antioxidants (vitamins E and C)
Trial: 12683261
Drug: Conventional antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antipsychotic treatment
Trial: 6202571
Drug: Mexiletine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (600 mg daily, 200 mg every 8 hours)
Trial: 6180562
Drug: Mexiletine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (600 mg daily)
Trial: 22999066
Drug: Gin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gin (30 g alcohol/d)
Trial: 22550117
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human IL-7 (rhIL-7) at a dose of 20 µg/kg
Trial: 17852016
Drug: Sequential trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential trial design
Trial: 9260077
Drug: Caffeinated cola
RxNorm normalized name: cola extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated cola (33 mg/8 oz)
Trial: 3812057
Drug: basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: basic treatment plus significant other support condition
Trial: 17012443
Drug: Both 12-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both 12-hour and 24-hour magnesium sulfate (MgSO4) therapy
Trial: 11078488
Drug: Anastrozole 1
RxNorm normalized name: anastrozole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg once daily
Trial: 11078488
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg once daily
Trial: 24841020
Drug: Caudal block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal block with 1 ml/kg bupivacaine 0.25% combined with 1 μg/kg clonidine
Trial: 24841020
Drug: Ilioinguinal-iliohypogastric nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilioinguinal-iliohypogastric nerve block with 0.3 ml/kg bupivacaine 0.25% combined with 1 μg/kg clonidine
Trial: 23545284
Drug: CVI of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVI of 5‐Fluorouracil (5‐FU), 225 mg/m(2) per day, 7 days per week plus pelvic hyperfractionated radiation (HRT), 45.6 Gy at 1.2 Gy twice daily plus a boost of 9.6 to 14.4 Gy for T3 or T4 cancers (Arm 1)
Trial: 20004739
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition designed to provide 100% of measured resting energy expenditure (REE)
Trial: 20004739
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition designed to provide 100% of measured REE
Trial: 20004739
Drug: Standard parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard parenteral nutrition (140% of estimated energy expenditure)
Trial: 18262380
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment using sulfadoxine‐pyrimethamine
Trial: 18262380
Drug: Weekly chemoprophylaxis
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly chemoprophylaxis with chloroquine
Trial: 18262380
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment using three doses of chloroquine
Trial: 16841626
Drug: Duloxetine (40-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (40-120 mg/day)
Trial: 12798153
Drug: EC40 (40%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC40 (40% chlorhexidine) applied once or twice over 2 weeks
Trial: 10900675
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens and combined progestin treatment
Trial: 1503446
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (4 x 850 mg tablets taken 5 min before Cipro)
Trial: 6147695
Drug: Breathing retraining
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breathing retraining followed by 7 weekly sessions of real-life exposure
Trial: 24613367
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron administration (510 mg elemental iron as ferumoxytol)
Trial: 7693422
Drug: Cyclophosphamide 100
RxNorm normalized name: cyclophosphamide 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 100 mg/m2 orally on days 1 to 14, Methotrexate 40 mg/m2 intravenously on days 1 and 8, Fluorouracil 600 mg/m2 intravenously on days 1 and 8 every 4 weeks for 6 cycles (CMF)
Trial: 7693422
Drug: Fluorouracil 600
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil 600 mg/m2, Epirubicin 50 mg/m2, Cyclophosphamide 600 mg/m2 (FEC), all given intravenously on day 1 for 8 cycles at 3-week intervals
Trial: 23566267
Drug: Subcutaneous 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous 1.0% lidocaine injection
Trial: 19098852
Drug: Extended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended treatment with peginterferon plus ribavirin for 48-68 weeks (44 weeks after HCV RNA negative)
Trial: 15915396
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) epinephrine
Trial: 7899535
Drug: L-5-hydroxytryptophan (L-5-HTP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-5-hydroxytryptophan (L-5-HTP, 200 mg PO)
Trial: 7899535
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 mg PO)
Trial: 857761
Drug: High epidural
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High epidural analgesia (bupivacaine injections into the epidural space)
Trial: 28551167
Drug: Brolucizumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brolucizumab (6 mg/50 μl)
Trial: 11591407
Drug: 1.125 g
RxNorm normalized name: progesterone 45 mg in 1.125 g VAGINAL GEL [Crinone]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.125 g of Crinone 4% and 8% or 2.25 g of Crinone 8% (containing 45, 90, and 180 mg of P per application)
Trial: 11591407
Drug: Vaginal P
RxNorm normalized name: Vaginal Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal P gel Crinone administered to estrogenized women
Trial: 7524044
Drug: Entex LA
RxNorm normalized name: Entex LA
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entex LA tablets (sustained-release, carbomer-based)
Trial: 7524044
Drug: Entex PSE
RxNorm normalized name: Entex PSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entex PSE tablets (sustained-release, hydroxypropylcellulose-based)
Trial: 7524044
Drug: Branded competitor
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded competitor products (sustained-release)
Trial: 2082492
Drug: Oral dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dipyridamole
Trial: 7593525
Drug: Gonadotrophin‐releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotrophin‐releasing hormone analogues (GnRHa)
Trial: 28706429
Drug: Reduced-dose sodium
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose sodium phosphate (NaP) tablets with 2 L of clear liquid (30 tablets)
Trial: 17047260
Drug: No model-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No model-based calculation algorithm or model-based calculation algorithm with a dose kernel unscaled for heterogeneities
Trial: 12660409
Drug: Cr (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cr (4 x 5 g x day(‐1) x 5 days)
Trial: 12660409
Drug: Glucose+Cr (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose+Cr (1 g x (‐1) of body mass twice per day)
Trial: 12660409
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g x day(‐1) maintenance
Trial: 12660409
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g x day(‐1) maintenance
Trial: 6619453
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion at midnight
Trial: 31091374
Drug: Alpelisib (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpelisib (300 mg per day) plus Fulvestrant (500 mg every 28 days and once on day 15)
Trial: 21784413
Drug: COMET +
RxNorm normalized name: Cometriq
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: COMET + treatment-as-usual (TAU)
Trial: 15313689
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition group (TPN group), 50 patients
Trial: 11273211
Drug: Prednisone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 0.5 mg/kg daily for 8 weeks
Trial: 9294477
Drug: TAM +
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAM + MPA (medroxyprogesterone acetate 500 mg/day orally)
Trial: 3779498
Drug: Rapid-sequence induction
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid-sequence induction with thiopentone (5 mg X kg‐1) and succinylcholine
Trial: 3779498
Drug: Elective induction
RxNorm normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective induction with thiopentone (5 mg X kg‐1) and succinylcholine
Trial: 22460142
Drug: Tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg
Trial: 31713350
Drug: Tofacitinib 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 15 mg (single dose) followed by 15 mg twice daily for 5 days
Trial: 25396067
Drug: Atorvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin treatment
Trial: 26276658
Drug: No-statin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-statin treatment (Control)
Trial: 21348544
Drug: Resveratrol-containing gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol-containing gel applied daily for 60 days on the right side of the face
Trial: 18301313
Drug: iomeprol-400 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iomeprol-400 (400 mgI/mL, 726 mOsm/kg, N = 76)
Trial: 17159170
Drug: All-polyethylene tibial
RxNorm normalized name: polyethylenes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All-polyethylene tibial implants
Trial: 17159170
Drug: Metal-backed tibial
RxNorm normalized name: menthone 1,2-glycerol ketal, (-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metal-backed tibial implants
Trial: 6404880
Drug: Ornidazole 500
RxNorm normalized name: ornidazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornidazole 500 mg orally every 12 h for seven days
Trial: 6404880
Drug: Phenoxymethylpenicillin 800
RxNorm normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenoxymethylpenicillin 800 mg orally every 12 h for seven days
Trial: 27742968
Drug: Ultrasound-guided intermediate
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided intermediate cervical plexus block with 5 ml of 0.75% ropivacaine
Trial: 19855076
Drug: Segmental muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Segmental muscle vibration (SMV) at 120 Hz for 30 minutes after each physical therapy session
Trial: 25591053
Drug: General physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General physical therapy
Trial: 12011283
Drug: Anti-NF-L antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-NF-L antibodies in PPMS and SPMS
Trial: 12011283
Drug: Anti-NF-L antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-NF-L antibodies
Trial: 7710795
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of a small amount of contrast medium rapidly via the antecubital vein and measurement of aortic transit time (ATT) by single slice dynamic CT.
Trial: 7710795
Drug: Spiral scanning
RxNorm normalized name: Trichinella spiralis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiral scanning of the liver using thin collimation and caudo-cranial table movement beginning at ATT after the end of contrast medium injection.
Trial: 2838426
Drug: Oral iodized
RxNorm normalized name: calcium iodized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iodized oil (2 ml)
Trial: 2838426
Drug: Intramuscular iodized
RxNorm normalized name: calcium iodized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular iodized oil (2 ml)
Trial: 407559
Drug: Betamethasone valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone valerate (BV, 800 microgram daily)
Trial: 407559
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (SCG, 80 mg daily)
Trial: 29679637
Drug: Non-reactive stimulant
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-reactive stimulant users (n=28)
Trial: 28271623
Drug: Probiotic capsule
RxNorm normalized name: GNP Probiotic Capsule
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic capsule (BIO-25), twice daily for 8 weeks